Overview

* Xeris Biopharma ( XERS ) Q2 revenue grows 49% YoY to $71.5 mln, driven by Recorlev

* Product revenue for Q2 beats analyst expectations, per LSEG data

* Company raises full-year revenue guidance to $280-$290 mln

Outlook

* Xeris raises full-year 2025 revenue guidance to $280-$290 mln

* Company projects $750 mln total revenue by 2030

* Xeris expects Recorlev net revenue to reach $1 bln by 2035

* Company anticipates XP-8121 peak net revenue of $1-$3 bln

Result Drivers

* RECORLEV DEMAND - Revenue growth driven by 136% increase in Recorlev sales due to higher patient numbers

* GVOKE PRESCRIPTIONS - 17% revenue increase attributed to prescription growth and favorable pricing

* KEVEYIS SHIPMENTS - 13% revenue decline due to reduced product shipments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $67.71 $64.60

Product mln mln (4

Revenue Analysts

)

Q2 Net -$1.93

Income mln

Q2 Basic -$0.01

EPS

Q2 $4.48

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc ( XERS ) is $7.00, about 21.6% above its August 6 closing price of $5.49

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)